Quantisnow Logo
Dashboard

Amendment: SEC Form SC 13G/A filed by 23andMe Holding Co.

$ME
Biotechnology: Pharmaceutical Preparations
Health Care
Get the next $ME alert in real time by email
SC 13G/A 1 d631579dsc13ga.htm SC 13G/A SC 13G/A

 

 

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

SCHEDULE 13G

(Rule 13d-102)

Information to be Included in Statements Filed Pursuant to § 240.13d-1(b), (c) and (d) and

Amendments Thereto Filed Pursuant to § 240.13d-2

Under the Securities Exchange Act of 1934

(Amendment No. 1)*

 

 

23andMe Holding Co.

(Name of Issuer)

Class A Common Stock, par value $0.0001 per share

(Title of Class of Securities)

90138Q306**

(CUSIP Number)

September 30, 2024

(Date of Event Which Requires Filing of this Statement)

 

 

Check the appropriate box to designate the rule pursuant to which this schedule is filed:

☐ Rule 13d-1(b)

☒ Rule 13d-1(c)

☐ Rule 13d-1(d)

 

*

The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

 

**

This CUSIP number applies to the Issuer’s Class A Common Stock.

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

 

 

 1   

 NAME OF REPORTING PERSON

 

 SEQUOIA CAPITAL GROWTH FUND III, L.P. (“SEQUOIA CAPITAL GROWTH FUND III”)

 2  

 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

 (a) ☐  (b) ☐

 

 3  

 SEC USE ONLY

 

 4  

 CITIZENSHIP OR PLACE OF ORGANIZATION

 

 DELAWARE

NUMBER OF

SHARES  BENEFICIALLY 

OWNED BY

EACH

REPORTING

PERSON

WITH

    5   

 SOLE VOTING POWER

 

 0

   6  

 SHARED VOTING POWER

 

 181,716, of which 181,716 are Class B shares

   7  

 SOLE DISPOSITIVE POWER

 

 0

   8  

 SHARED DISPOSITIVE POWER

 

 181,716, of which 181,716 are Class B shares

 9   

 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

 181,716

10  

 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

 

 ☐

11  

 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

 

 1.0%1

12  

 TYPE OF REPORTING PERSON

 

 PN

 

1

Based on a total of 17,514,628 shares of Class A Common Stock outstanding as of October 16, 2024, as reported in the Issuer’s Current Report on Form 8-K filed with the Securities and Exchange Commission on October 16, 2024.

 1   

 NAME OF REPORTING PERSON

 

 SEQUOIA CAPITAL U.S. GROWTH FUND VII, L.P. (“SEQUOIA CAPITAL U.S. GROWTH FUND VII”)

 2  

 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

 (a) ☐  (b) ☐

 

 3  

 SEC USE ONLY

 

 4  

 CITIZENSHIP OR PLACE OF ORGANIZATION

 

 CAYMAN ISLANDS

NUMBER OF

SHARES  BENEFICIALLY 

OWNED BY

EACH

REPORTING

PERSON

WITH

    5   

 SOLE VOTING POWER

 

 0

   6  

 SHARED VOTING POWER

 

 306,783, of which 306,783 are Class B shares

   7  

 SOLE DISPOSITIVE POWER

 

 0

   8  

 SHARED DISPOSITIVE POWER

 

 306,783, of which 306,783 are Class B shares

 9   

 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

 306,783

10  

 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

 

 ☐

11  

 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

 

 1.7%1

12  

 TYPE OF REPORTING PERSON

 

 PN

 

1

Based on a total of 17,514,628 shares of Class A Common Stock outstanding as of October 16, 2024, as reported in the Issuer’s Current Report on Form 8-K filed with the Securities and Exchange Commission on October 16, 2024.

 1   

 NAME OF REPORTING PERSON

 

SEQUOIA CAPITAL U.S. GROWTH VII PRINCIPALS FUND, L.P. (“SEQUOIA CAPITAL U.S. GROWTH VII PRINCIPALS FUND”)

 2  

 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

 (a) ☐  (b) ☐

 

 3  

 SEC USE ONLY

 

 4  

 CITIZENSHIP OR PLACE OF ORGANIZATION

 

 CAYMAN ISLANDS

NUMBER OF

SHARES  BENEFICIALLY 

OWNED BY

EACH

REPORTING

PERSON

WITH

    5   

 SOLE VOTING POWER

 

 0

   6  

 SHARED VOTING POWER

 

 25,235, of which 25,235 are Class B shares

   7  

 SOLE DISPOSITIVE POWER

 

 0

   8  

 SHARED DISPOSITIVE POWER

 

 25,235, of which 25,235 are Class B shares

 9   

 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

 25,235

10  

 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

 

 ☐

11  

 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

 

 0.1%1

12  

 TYPE OF REPORTING PERSON

 

 PN

 

1

Based on a total of 17,514,628 shares of Class A Common Stock outstanding as of October 16, 2024, as reported in the Issuer’s Current Report on Form 8-K filed with the Securities and Exchange Commission on October 16, 2024.

 1   

 NAME OF REPORTING PERSON

 

 SEQUOIA CAPITAL U.S. GROWTH FUND VIII, L.P. (“SEQUOIA CAPITAL U.S. GROWTH FUND VIII”)

 2  

 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

 (a) ☐  (b) ☐

 

 3  

 SEC USE ONLY

 

 4  

 CITIZENSHIP OR PLACE OF ORGANIZATION

 

 CAYMAN ISLANDS

NUMBER OF

SHARES  BENEFICIALLY 

OWNED BY

EACH

REPORTING

PERSON

WITH

    5   

 SOLE VOTING POWER

 

 0

   6  

 SHARED VOTING POWER

 

 190,917, of which 190,917 are Class B shares

   7  

 SOLE DISPOSITIVE POWER

 

 0

   8  

 SHARED DISPOSITIVE POWER

 

 190,917, of which 190,917 are Class B shares

 9   

 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

 190,917

10  

 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

 

 ☐

11  

 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

 

 1.1%1

12  

 TYPE OF REPORTING PERSON

 

 PN

 

1

Based on a total of 17,514,628 shares of Class A Common Stock outstanding as of October 16, 2024, as reported in the Issuer’s Current Report on Form 8-K filed with the Securities and Exchange Commission on October 16, 2024.

 1   

 NAME OF REPORTING PERSON

 

 SEQUOIA CAPITAL GLOBAL GROWTH FUND II, L.P. (“SEQUOIA CAPITAL GLOBAL GROWTH FUND II”)

 2  

 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

 (a) ☐  (b) ☐

 

 3  

 SEC USE ONLY

 

 4  

 CITIZENSHIP OR PLACE OF ORGANIZATION

 

 CAYMAN ISLANDS

NUMBER OF

SHARES  BENEFICIALLY 

OWNED BY

EACH

REPORTING

PERSON

WITH

    5   

 SOLE VOTING POWER

 

 0

   6  

 SHARED VOTING POWER

 

 183,516, of which 183,516 are Class B shares

   7  

 SOLE DISPOSITIVE POWER

 

 0

   8  

 SHARED DISPOSITIVE POWER

 

 183,516, of which 183,516 are Class B shares

 9   

 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

 183,516

10  

 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

 

 ☐

11  

 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

 

 1.0%1

12  

 TYPE OF REPORTING PERSON

 

 PN

 

1

Based on a total of 17,514,628 shares of Class A Common Stock outstanding as of October 16, 2024, as reported in the Issuer’s Current Report on Form 8-K filed with the Securities and Exchange Commission on October 16, 2024.

 1   

 NAME OF REPORTING PERSON

 

SEQUOIA CAPITAL GLOBAL GROWTH II PRINCIPALS FUND, L.P. (“SEQUOIA CAPITAL GLOBAL GROWTH II PRINCIPALS FUND”)

 2  

 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

 (a) ☐  (b) ☐

 

 3  

 SEC USE ONLY

 

 4  

 CITIZENSHIP OR PLACE OF ORGANIZATION

 

 CAYMAN ISLANDS

NUMBER OF

SHARES  BENEFICIALLY 

OWNED BY

EACH

REPORTING

PERSON

WITH

    5   

 SOLE VOTING POWER

 

 0

   6  

 SHARED VOTING POWER

 

 2,758, of which 2,758 are Class B shares

   7  

 SOLE DISPOSITIVE POWER

 

 0

   8  

 SHARED DISPOSITIVE POWER

 

 2,758, of which 2,758 are Class B shares

 9   

 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

 2,758

10  

 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

 

 ☐

11  

 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

 

 Less than 0.1%1

12  

 TYPE OF REPORTING PERSON

 

 PN

 

1

Based on a total of 17,514,628 shares of Class A Common Stock outstanding as of October 16, 2024, as reported in the Issuer’s Current Report on Form 8-K filed with the Securities and Exchange Commission on October 16, 2024.

 1   

 NAME OF REPORTING PERSON

 

 SCGF III MANAGEMENT, LLC (“SCGF III MANAGEMENT”)

 2  

 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

 (a) ☐  (b) ☐

 

 3  

 SEC USE ONLY

 

 4  

 CITIZENSHIP OR PLACE OF ORGANIZATION

 

 DELAWARE

NUMBER OF

SHARES  BENEFICIALLY 

OWNED BY

EACH

REPORTING

PERSON

WITH

    5   

 SOLE VOTING POWER

 

 0

   6  

 SHARED VOTING POWER

 

181,716, of which 181,716 are Class B shares directly owned by SEQUOIA CAPITAL GROWTH FUND III. The general partner of SEQUOIA CAPITAL GROWTH FUND III is SCGF III MANAGEMENT.

   7  

 SOLE DISPOSITIVE POWER

 

 0

   8  

 SHARED DISPOSITIVE POWER

 

181,716, of which 181,716 are Class B shares directly owned by SEQUOIA CAPITAL GROWTH FUND III. The general partner of SEQUOIA CAPITAL GROWTH FUND III is SCGF III MANAGEMENT.

 9   

 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

 181,716

10  

 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

 

 ☐

11  

 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

 

 1.0%1

12  

 TYPE OF REPORTING PERSON

 

 OO

 

1

Based on a total of 17,514,628 shares of Class A Common Stock outstanding as of October 16, 2024, as reported in the Issuer’s Current Report on Form 8-K filed with the Securities and Exchange Commission on October 16, 2024.

 1   

 NAME OF REPORTING PERSON

 

 SC U.S. GROWTH VII MANAGEMENT, L.P. (“SC U.S. GROWTH VII MANAGEMENT”)

 2  

 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

 (a) ☐  (b) ☐

 

 3  

 SEC USE ONLY

 

 4  

 CITIZENSHIP OR PLACE OF ORGANIZATION

 

 CAYMAN ISLANDS

NUMBER OF

SHARES  BENEFICIALLY 

OWNED BY

EACH

REPORTING

PERSON

WITH

    5   

 SOLE VOTING POWER

 

 0

   6  

 SHARED VOTING POWER

 

332,018, of which 306,783 are Class B shares directly owned by SEQUOIA CAPITAL U.S. GROWTH FUND VII and 25,235 are Class B shares directly owned by SEQUOIA CAPITAL U.S. GROWTH VII PRINCIPALS FUND. The General Partner of each of SEQUOIA CAPITAL U.S. GROWTH FUND VII and SEQUOIA CAPITAL U.S. GROWTH FUND VII PRINCIPALS FUND is SC U.S. GROWTH VII MANAGEMENT.

   7  

 SOLE DISPOSITIVE POWER

 

 0

   8  

 SHARED DISPOSITIVE POWER

 

332,018, of which 306,783 are Class B shares directly owned by SEQUOIA CAPITAL U.S. GROWTH FUND VII and 25,235 are Class B shares directly owned by SEQUOIA CAPITAL U.S. GROWTH VII PRINCIPALS FUND. The General Partner of each of SEQUOIA CAPITAL U.S. GROWTH FUND VII and SEQUOIA CAPITAL U.S. GROWTH FUND VII PRINCIPALS FUND is SC U.S. GROWTH VII MANAGEMENT.

 9   

 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

 332,018

10  

 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

 

 ☐

11  

 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

 

 1.9%1

12  

 TYPE OF REPORTING PERSON

 

 PN

 

1

Based on a total of 17,514,628 shares of Class A Common Stock outstanding as of October 16, 2024, as reported in the Issuer’s Current Report on Form 8-K filed with the Securities and Exchange Commission on October 16, 2024.

 1   

 NAME OF REPORTING PERSON

 

 SC U.S. GROWTH VIII MANAGEMENT, L.P. (“SC U.S. GROWTH VIII MANAGEMENT”)

 2  

 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

 (a) ☐  (b) ☐

 

 3  

 SEC USE ONLY

 

 4  

 CITIZENSHIP OR PLACE OF ORGANIZATION

 

 CAYMAN ISLANDS

NUMBER OF

SHARES  BENEFICIALLY 

OWNED BY

EACH

REPORTING

PERSON

WITH

    5    

 SOLE VOTING POWER

 

 0

   6   

 SHARED VOTING POWER

 

190,917, of which 190,917 are Class B shares directly owned by SEQUOIA CAPITAL U.S. GROWTH FUND VIII. The General Partner of SEQUOIA CAPITAL U.S. GROWTH FUND VIII is SC U.S. GROWTH VIII MANAGEMENT.

   7   

 SOLE DISPOSITIVE POWER

 

 0

   8   

 SHARED DISPOSITIVE POWER

 

190,917, of which 190,917 are Class B shares directly owned by SEQUOIA CAPITAL U.S. GROWTH FUND VIII. The General Partner of SEQUOIA CAPITAL U.S. GROWTH FUND VIII is SC U.S. GROWTH VIII MANAGEMENT.

 9   

 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

 190,917

10  

 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

 

 ☐

11  

 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

 

 1.1%1

12  

 TYPE OF REPORTING PERSON

 

 PN

 

1

Based on a total of 17,514,628 shares of Class A Common Stock outstanding as of October 16, 2024, as reported in the Issuer’s Current Report on Form 8-K filed with the Securities and Exchange Commission on October 16, 2024.

 1   

 NAME OF REPORTING PERSON

 

 SC GLOBAL GROWTH II MANAGEMENT, L.P. (“SC GLOBAL GROWTH II MANAGEMENT”)

 2  

 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

 (a) ☐  (b) ☐

 

 3  

 SEC USE ONLY

 

 4  

 CITIZENSHIP OR PLACE OF ORGANIZATION

 

 CAYMAN ISLANDS

NUMBER OF

SHARES  BENEFICIALLY 

OWNED BY

EACH

REPORTING

PERSON

WITH

    5    

 SOLE VOTING POWER

 

 0

   6   

 SHARED VOTING POWER

 

186,274 shares, of which 183,516 are Class B shares directly owned by SEQUOIA CAPITAL GLOBAL GROWTH FUND II and 2,758 are Class B shares directly owned by SEQUOIA CAPITAL GLOBAL GROWTH II PRINCIPALS FUND. The General Partner of each of SEQUOIA CAPITAL GLOBAL GROWTH FUND II and SEQUOIA CAPITAL GLOBAL GROWTH FUND II PRINCIPALS FUND is SC GLOBAL GROWTH II MANAGEMENT.

   7   

 SOLE DISPOSITIVE POWER

 

 0

   8   

 SHARED DISPOSITIVE POWER

 

186,274 shares, of which 183,516 are Class B shares directly owned by SEQUOIA CAPITAL GLOBAL GROWTH FUND II and 2,758 are Class B shares directly owned by SEQUOIA CAPITAL GLOBAL GROWTH II PRINCIPALS FUND. The General Partner of each of SEQUOIA CAPITAL GLOBAL GROWTH FUND II and SEQUOIA CAPITAL GLOBAL GROWTH FUND II PRINCIPALS FUND is SC GLOBAL GROWTH II MANAGEMENT.

 9   

 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

 186,274

10  

 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

 

 ☐

11  

 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

 

 1.1%1

12  

 TYPE OF REPORTING PERSON

 

 PN

 

1

Based on a total of 17,514,628 shares of Class A Common Stock outstanding as of October 16, 2024, as reported in the Issuer’s Current Report on Form 8-K filed with the Securities and Exchange Commission on October 16, 2024.

 1   

 NAME OF REPORTING PERSON

 

 SC US (TTGP), LTD. (“SC US (TTGP)”)

 2  

 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

 (a) ☐  (b) ☐

 

 3  

 SEC USE ONLY

 

 4  

 CITIZENSHIP OR PLACE OF ORGANIZATION

 

 CAYMAN ISLANDS

NUMBER OF

SHARES  BENEFICIALLY 

OWNED BY

EACH

REPORTING

PERSON

WITH

    5    

 SOLE VOTING POWER

 

 0

   6   

 SHARED VOTING POWER

 

709,209 shares, of which 306,783 are Class B shares directly owned by SEQUOIA CAPITAL U.S. GROWTH FUND VII, 25,235 are Class B shares directly owned by SEQUOIA CAPITAL U.S. GROWTH VII PRINCIPALS FUND, 190,917 are Class B shares directly owned by SEQUOIA CAPITAL U.S. GROWTH FUND VIII, 183,516 are Class B shares directly owned by SEQUOIA CAPITAL GLOBAL GROWTH FUND II and 2,758 are Class B shares directly owned by SEQUOIA CAPITAL GLOBAL GROWTH II PRINCIPALS FUND. The General Partner of each of SEQUOIA CAPITAL U.S. GROWTH FUND VII and SEQUOIA CAPITAL U.S. GROWTH FUND VII PRINCIPALS FUND is SC U.S. GROWTH VII MANAGEMENT. The General Partner of SEQUOIA CAPITAL U.S. GROWTH FUND VIII is SC U.S. GROWTH VIII MANAGEMENT. The General Partner of each of SEQUOIA CAPITAL GLOBAL GROWTH FUND II and SEQUOIA CAPITAL GLOBAL GROWTH FUND II PRINCIPALS FUND is SC GLOBAL GROWTH II MANAGEMENT. SC US (TTGP) is the General Partner of each of SC U.S. GROWTH VII MANAGEMENT, SC U.S. GROWTH VIII MANAGEMENT and SC GLOBAL GROWTH II MANAGEMENT.

   7   

 SOLE DISPOSITIVE POWER

 

 0

   8   

 SHARED DISPOSITIVE POWER

 

709,209 shares, of which 306,783 are Class B shares directly owned by SEQUOIA CAPITAL U.S. GROWTH FUND VII, 25,235 are Class B shares directly owned by SEQUOIA CAPITAL U.S. GROWTH VII PRINCIPALS FUND, 190,917 are Class B shares directly owned by SEQUOIA CAPITAL U.S. GROWTH FUND VIII, 183,516 are Class B shares directly owned by SEQUOIA CAPITAL GLOBAL GROWTH FUND II and 2,758 are Class B shares directly owned by SEQUOIA CAPITAL GLOBAL GROWTH II PRINCIPALS FUND. The General Partner of each of SEQUOIA CAPITAL U.S. GROWTH FUND VII and SEQUOIA CAPITAL U.S. GROWTH FUND VII PRINCIPALS FUND is SC U.S. GROWTH VII MANAGEMENT. The General Partner of SEQUOIA CAPITAL U.S. GROWTH FUND VIII is SC U.S. GROWTH VIII MANAGEMENT. The General Partner of each of SEQUOIA CAPITAL GLOBAL GROWTH FUND II and SEQUOIA CAPITAL GLOBAL GROWTH FUND II PRINCIPALS FUND is SC GLOBAL GROWTH II MANAGEMENT. SC US (TTGP) is the General Partner of each of SC U.S. GROWTH VII MANAGEMENT, SC U.S. GROWTH VIII MANAGEMENT and SC GLOBAL GROWTH II MANAGEMENT.

 9   

 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

 709,209

10  

 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

 

 ☐

11  

 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

 

 3.9%1

12  

 TYPE OF REPORTING PERSON

 

 PN

 

1

Based on a total of 17,514,628 shares of Class A Common Stock outstanding as of October 16, 2024, as reported in the Issuer’s Current Report on Form 8-K filed with the Securities and Exchange Commission on October 16, 2024.

 1   

 NAME OF REPORTING PERSON

 

 DOUGLAS LEONE (“DL”)

 2  

 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

 (a) ☐  (b) ☐

 

 3  

 SEC USE ONLY

 

 4  

 CITIZENSHIP OR PLACE OF ORGANIZATION

 

 USA

NUMBER OF

SHARES  BENEFICIALLY 

OWNED BY

EACH

REPORTING

PERSON

WITH

    5   

 SOLE VOTING POWER

 

 33,846

   6  

 SHARED VOTING POWER

 

186,274 shares, of which 183,516 are Class B shares directly owned by SEQUOIA CAPITAL GLOBAL GROWTH FUND II and 2,758 are Class B shares directly owned by SEQUOIA CAPITAL GLOBAL GROWTH II PRINCIPALS FUND. The General Partner of each of SEQUOIA CAPITAL GLOBAL GROWTH FUND II and SEQUOIA CAPITAL GLOBAL GROWTH FUND II PRINCIPALS FUND is SC GLOBAL GROWTH II MANAGEMENT. SC US (TTGP) is the General Partner of SC GLOBAL GROWTH II MANAGEMENT. The directors and stockholders of SC US (TTGP) who exercise voting and investment discretion with respect to the shares held by SEQUOIA CAPITAL GLOBAL GROWTH FUND II and SEQUOIA CAPITAL GLOBAL GROWTH II PRINCIPALS FUND are Messrs. DL and RB.

   7  

 SOLE DISPOSITIVE POWER

 

 33,846

   8  

 SHARED DISPOSITIVE POWER

 

186,274 shares, of which 183,516 are Class B shares directly owned by SEQUOIA CAPITAL GLOBAL GROWTH FUND II and 2,758 are Class B shares directly owned by SEQUOIA CAPITAL GLOBAL GROWTH II PRINCIPALS FUND. The General Partner of each of SEQUOIA CAPITAL GLOBAL GROWTH FUND II and SEQUOIA CAPITAL GLOBAL GROWTH FUND II PRINCIPALS FUND is SC GLOBAL GROWTH II MANAGEMENT. SC US (TTGP) is the General Partner of SC GLOBAL GROWTH II MANAGEMENT. The directors and stockholders of SC US (TTGP) who exercise voting and investment discretion with respect to the shares held by SEQUOIA CAPITAL GLOBAL GROWTH FUND II and SEQUOIA CAPITAL GLOBAL GROWTH II PRINCIPALS FUND are Messrs. DL and RB.

 9   

 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

 220,120

10  

 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

 

 ☐

11  

 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

 

 1.2%1

12  

 TYPE OF REPORTING PERSON

 

 IN

 

1

Based on a total of 17,514,628 shares of Class A Common Stock outstanding as of October 16, 2024, as reported in the Issuer’s Current Report on Form 8-K filed with the Securities and Exchange Commission on October 16, 2024.

 1   

 NAME OF REPORTING PERSON

 

 ROELOF BOTHA (“RB”)

 2  

 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

 (a) ☐  (b) ☐

 

 3  

 SEC USE ONLY

 

 4  

 CITIZENSHIP OR PLACE OF ORGANIZATION

 

 USA

NUMBER OF

SHARES  BENEFICIALLY 

OWNED BY

EACH

REPORTING

PERSON

WITH

    5   

 SOLE VOTING POWER

 

 55,385

   6  

 SHARED VOTING POWER

 

186,274 shares, of which 183,516 are Class B shares directly owned by SEQUOIA CAPITAL GLOBAL GROWTH FUND II and 2,758 are Class B shares directly owned by SEQUOIA CAPITAL GLOBAL GROWTH II PRINCIPALS FUND. The General Partner of each of SEQUOIA CAPITAL GLOBAL GROWTH FUND II and SEQUOIA CAPITAL GLOBAL GROWTH FUND II PRINCIPALS FUND is SC GLOBAL GROWTH II MANAGEMENT. SC US (TTGP) is the General Partner of SC GLOBAL GROWTH II MANAGEMENT. The directors and stockholders of SC US (TTGP) who exercise voting and investment discretion with respect to the shares held by SEQUOIA CAPITAL GLOBAL GROWTH FUND II and SEQUOIA CAPITAL GLOBAL GROWTH II PRINCIPALS FUND are Messrs. DL and RB.

   7  

 SOLE DISPOSITIVE POWER

 

 55,385

   8  

 SHARED DISPOSITIVE POWER

 

186,274 shares, of which 183,516 are Class B shares directly owned by SEQUOIA CAPITAL GLOBAL GROWTH FUND II and 2,758 are Class B shares directly owned by SEQUOIA CAPITAL GLOBAL GROWTH II PRINCIPALS FUND. The General Partner of each of SEQUOIA CAPITAL GLOBAL GROWTH FUND II and SEQUOIA CAPITAL GLOBAL GROWTH FUND II PRINCIPALS FUND is SC GLOBAL GROWTH II MANAGEMENT. SC US (TTGP) is the General Partner of SC GLOBAL GROWTH II MANAGEMENT. The directors and stockholders of SC US (TTGP) who exercise voting and investment discretion with respect to the shares held by SEQUOIA CAPITAL GLOBAL GROWTH FUND II and SEQUOIA CAPITAL GLOBAL GROWTH II PRINCIPALS FUND are Messrs. DL and RB.

 9   

 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

 241,659

10  

 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

 

 ☐

11  

 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

 

 1.4%1

12  

 TYPE OF REPORTING PERSON

 

 IN

 

1

Based on a total of 17,514,628 shares of Class A Common Stock outstanding as of October 16, 2024, as reported in the Issuer’s Current Report on Form 8-K filed with the Securities and Exchange Commission on October 16, 2024.

ITEM 1.

(a) Name of Issuer:

23andMe Holding Co.

(b) Address of Issuer’s Principal Executive Offices:

223 N. Mathilda Avenue

Sunnyvale, California 94086

 

ITEM 2.

(a) Name of Persons Filing:

Sequoia Capital Growth Fund III, L.P.

Sequoia Capital U.S. Growth Fund VII, L.P.

Sequoia Capital U.S. Growth VII Principals Fund, L.P.

Sequoia Capital U.S. Growth Fund VIII, L.P.

Sequoia Capital Global Growth Fund II, L.P.

Sequoia Capital Global Growth II Principals Fund, L.P.

SCGF III Management, L.P.

SC U.S. Growth VII Management, L.P.

SC U.S. Growth VIII Management, L.P.

SC Global Growth II Management, L.P.

SC US (TTPG), Ltd.

Douglas Leone

Roelof Botha

The general partner of SEQUOIA CAPITAL GROWTH FUND III is SCGF III MANAGEMENT.

The General Partner of each of SEQUOIA CAPITAL U.S. GROWTH FUND VII and SEQUOIA CAPITAL U.S. GROWTH FUND VII PRINCIPALS FUND is SC U.S. GROWTH VII MANAGEMENT. SC US (TTGP) is the General Partner of SC U.S. GROWTH VII MANAGEMENT.

The General Partner of SEQUOIA CAPITAL U.S. GROWTH FUND VIII is SC U.S. GROWTH VIII MANAGEMENT. SC US (TTGP) is the General Partner of SC U.S. GROWTH VIII MANAGEMENT.

The General Partner of each of SEQUOIA CAPITAL GLOBAL GROWTH FUND II and SEQUOIA CAPITAL GLOBAL GROWTH FUND II PRINCIPALS FUND is SC GLOBAL GROWTH II MANAGEMENT. SC US (TTGP) is the General Partner of SC GLOBAL GROWTH II MANAGEMENT. The directors and stockholders of SC US (TTGP) who exercise voting and investment discretion with respect to the shares held by SEQUOIA CAPITAL GLOBAL GROWTH FUND II and SEQUOIA CAPITAL GLOBAL GROWTH II PRINCIPALS FUND are Messrs. DL and RB.

(b) Address of Principal Business Office or, if none, Residence:

2800 Sand Hill Road, Suite 101

Menlo Park, CA 94025

(c) Citizenship:

SEQUOIA CAPITAL U.S. GROWTH FUND VII, SEQUOIA CAPITAL U.S. GROWTH FUND VII PRINCIPALS FUND, SEQUOIA CAPITAL U.S. GROWTH FUND VIII, SEQUOIA CAPITAL GLOBAL GROWTH FUND II, L.P., SEQUOIA CAPITAL GLOBAL GROWTH II PRINCIPALS FUND, L.P., SC U.S. GROWTH VII MANAGEMENT, L.P., SC U.S. GROWTH VIII MANAGEMENT, L.P., SC GLOBAL GROWTH II MANAGEMENT, L.P., SC US (TTGP), LTD., Cayman Islands

SEQUOIA CAPITAL GROWTH FUND III, SCGF III MANAGEMENT: Delaware

DL, RB: USA

(d) CUSIP Number:

90138Q306

ITEM 3.

If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

NOT APPLICABLE

 

ITEM 4.

OWNERSHIP

SEE ROWS 5 THROUGH 11 OF COVER PAGES

 

ITEM 5.

OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☒.

 

ITEM 6.

OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON

NOT APPLICABLE

 

ITEM 7.

IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY.

NOT APPLICABLE

 

ITEM 8.

IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP.

NOT APPLICABLE

 

ITEM 9.

NOTICE OF DISSOLUTION OF GROUP.

NOT APPLICABLE

 

ITEM 10.

CERTIFICATION

NOT APPLICABLE

SIGNATURES

After reasonable inquiry and to the best of my knowledge and belief, the undersigned certifies that the information set forth in this statement is true, complete and correct.

Dated: October 21, 2024

 

Sequoia Capital Growth Fund III, L.P.

By: SCGF III Management, LLC

its General Partner

By:  

/s/ Jung Yeon Son

  Jung Yeon Son, by power of attorney for Roelof Botha, Director

Sequoia Capital U.S. Growth Fund VII, L.P.

 

By: SC U.S. Growth VII Management, L.P.

its General Partner

 

By: SC US (TTGP), Ltd.

its General Partner

By:  

/s/ Jung Yeon Son

  Jung Yeon Son, by power of attorney for Roelof Botha, Director

Sequoia Capital U.S. Growth VII Principals Fund, L.P.

 

By: SC U.S. Growth VII Management, L.P.

its General Partner

 

By: SC US (TTGP), Ltd.

its General Partner

By:  

/s/ Jung Yeon Son

  Jung Yeon Son, by power of attorney for Roelof Botha, Director

Sequoia Capital U.S. Growth Fund VIII, L.P.

 

By: SC U.S. Growth VIII Management, L.P.

its General Partner

 

By: SC US (TTGP), Ltd.

its General Partner

By:  

/s/ Jung Yeon Son

  Jung Yeon Son, by power of attorney for Roelof Botha, Director

Sequoia Capital Global Growth Fund II, L.P.

By: SC Global Growth II Management, L.P.

its General Partner

By: SC US (TTGP), Ltd.

its General Partner

By:  

/s/ Jung Yeon Son

  Jung Yeon Son, by power of attorney for Roelof Botha, Director

Sequoia Capital Global Growth II Principals Fund, L.P.

 

By: SC Global Growth II Management, L.P.

its General Partner

 

By: SC US (TTGP), Ltd.

its General Partner

By:  

/s/ Jung Yeon Son

  Jung Yeon Son, by power of attorney for Roelof Botha, Director
SCGF III Management, LLC
By:  

/s/ Jung Yeon Son

  Jung Yeon Son, by power of attorney for Roelof Botha, Director

SC U.S. Growth VII Management, L.P.

 

By: SC US (TTGP), Ltd.

its General Partner

By:  

/s/ Jung Yeon Son

  Jung Yeon Son, by power of attorney for Roelof Botha, Director

SC U.S. Growth VIII Management, L.P.

 

By: SC US (TTGP), Ltd.

its General Partner

By:  

/s/ Jung Yeon Son

  Jung Yeon Son, by power of attorney for Roelof Botha, Director

SC Global Growth II Management, L.P.

 

By: SC US (TTGP), Ltd.

its General Partner

By:  

/s/ Jung Yeon Son

  Jung Yeon Son, by power of attorney for Roelof Botha, Director
SC US (TTGP), Ltd.
By:  

/s/ Jung Yeon Son

  Jung Yeon Son, by power of attorney for Roelof Botha, Director
Douglas Leone
By:  

/s/ Jung Yeon Son

  Jung Yeon Son, by power of attorney for Douglas Leone
Roelof Botha
By:  

/s/ Jung Yeon Son

 

Jung Yeon Son, by power of attorney for

Roelof Botha
Get the next $ME alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$ME

DatePrice TargetRatingAnalyst
11/29/2022$7.00Buy
Berenberg
9/22/2022$6.00Outperform
Cowen
2/11/2022$14.00 → $11.00Outperform
Credit Suisse
12/20/2021$13.00 → $9.00Neutral
Citigroup
11/15/2021$12.00 → $13.00Buy → Neutral
Citigroup
11/11/2021$13.00 → $14.00Outperform
Credit Suisse
8/17/2021$13.00Outperform
Credit Suisse
7/12/2021$14.00Buy
Citigroup
More analyst ratings

$ME
 Press Releases

Fastest customizable press release news feed in the world

See more

  • 23andMe Confirms All Potential Buyers Must Agree to Comply With Privacy Policy and Applicable Law

    SAN FRANCISCO, March 26, 2025 (GLOBE NEWSWIRE) -- 23andMe Holding Co. ("23andMe" or the "Company") (NASDAQ:ME), a leading human genetics and biotechnology company, today announced that it has received approvals from the U.S. Bankruptcy Court for the Eastern District of Missouri (the "Court") for its "first day" motions related to 23andMe's voluntary Chapter 11 petitions filed March 23, 2025, including authorization to pay employee wages and benefits and compensate certain vendors and suppliers in the ordinary course for goods and services provided and to enter into the binding term sheet for a $35 million debtor-in-possession financing facility from JMB Capital Partners (the "DIP Facility"

    $ME
    Biotechnology: Pharmaceutical Preparations
    Health Care

  • 23andMe Initiates Voluntary Chapter 11 Process to Maximize Stakeholder Value Through Court-Supervised Sale Process

    Intends to use Proceedings to Conduct a Value-Maximizing Sale Process and Resolve Liabilities Company Expects to Continue Business Operations in the Ordinary Course During Proceedings; Secures Commitment for Approximately $35 Million in DIP Financing to Support Ongoing Operations No Changes to Customer Data Management and Access; Company Remains Committed to Transparency Around Customer Data Privacy; Any Buyer will be Required to Comply with Applicable Law with Respect to Treatment of Customer Data Company Announces Board and Leadership Changes to Support Restructuring and Sale Process SAN FRANCISCO, March 23, 2025 (GLOBE NEWSWIRE) -- 23andMe Holding Co. ("23andMe" or the "Company") (

    $ME
    Biotechnology: Pharmaceutical Preparations
    Health Care

  • 23andMe Launches New Homocysteine (MTHFR-Related) Genetic Report and Accompanying Lab Test

    SAN FRANCISCO, March 21, 2025 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (NASDAQ:ME), a leading human genetics company with a mission to help people access, understand, and benefit from the human genome, today released a new report on the genetics of homocysteine levels for 23andMe+ Premium members, as well as a blood test for next steps in further understanding said levels for an additional fee. One of the top 23andMe customer requested reports, it informs users if they are at a higher likelihood of developing slightly elevated homocysteine levels along with actionable lifestyle factors that can reduce their chances. Homocysteine is an amino acid that plays a key role in important process

    $ME
    Biotechnology: Pharmaceutical Preparations
    Health Care

$ME
 Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$ME
 Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$ME
 SEC Filings

See more

$ME
 Leadership Updates

Live Leadership Updates

See more

  • 23andMe Appoints Three New Independent Directors to Board

    SUNNYVALE, Calif., Oct. 29, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (NASDAQ:ME) (the "Company" or "23andMe"), a leading human genetics and preventive health company, today announced the appointments of Andre Fernandez, Jim Frankola, and Mark Jensen, three accomplished and experienced executives, as independent members of the Company's Board of Directors (the "Board"), effective on October 28, 2024. Each of Mr. Fernandez, Mr. Frankola, and Mr. Jensen have been appointed to serve as members of the Board's Audit Committee and Compensation Committee, with Mr. Fernandez serving as the Chair of the Audit Committee and Mr. Jensen serving as the Chair of the Compensation Committee. In additio

    $ANSS
    $CDLX
    $LSCC
    $ME
    Computer Software: Prepackaged Software
    Technology
    Computer Software: Programming Data Processing
    Semiconductors

  • Madryn Asset Management, a Top Shareholder of SomaLogic, Issues Letter Regarding Opposition to the Company's Proposed Merger with Standard BioTools

    Files Preliminary Proxy Statement to Solicit Shareholders to Oppose the Merger Intends to Vote AGAINST the Conflict-Plagued and Excessively Dilutive Transaction, Which Stands to Unduly Benefit Certain Investors and Standard BioTools at the Expense of SomaLogic's Shareholders Notes the Current Premium for SomaLogic Shareholders, Based on the Deal's Exchange Ratio and Standard BioTools' Trading Price, is Only ~4.3% Underscores That SomaLogic Has Superior Alternatives to a Flawed Combination, Including a Standalone Path Leveraging its Considerable Cash Position and Strong Balance Sheet Madryn Asset Management, LP (collectively with its affiliates, "Madryn"), a holder of approximately 4

    $EXAS
    $ILMN
    $LAB
    $ME
    Medical Specialities
    Health Care
    Biotechnology: Laboratory Analytical Instruments
    Industrials

  • Reza Afkhami Joins 23andMe as Chief Corporate Development Officer

    SOUTH SAN FRANCISCO, Calif., May 08, 2023 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (NASDAQ:ME) ("23andMe"), a leading human genetics and biopharmaceutical company, today announced the appointment of Reza Afkhami as its Chief Corporate Development Officer overseeing corporate development efforts across its therapeutics, research services and consumer groups. Afkhami will be responsible for spearheading and driving a wide range of industry collaborations for the Company. 23andMe Therapeutics has a pipeline of genetically validated discovery and clinical programs, which it intends to advance through collaborations with pharmaceutical companies. Furthermore, 23andMe hopes to help the pharmac

    $ME
    Biotechnology: Pharmaceutical Preparations
    Health Care

$ME
 Financials

Live finance-specific insights

See more

  • 23andMe Reports Second Quarter Fiscal Year 2025 Financial Results

    SUNNYVALE, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (NASDAQ:ME), a leading human genetics and preventive health company, reported its financial results for the second quarter of fiscal year 2025 (FY25), which ended September 30, 2024. Key Results: Improved GAAP Net Loss by 21% and Adjusted EBITDA by 26% for the same period in the prior year (see important additional information below).The 23andMe comprehensive Total Health longevity service is now available to all customers, combining whole exome genetic sequencing with bi-annual lab tests for 55+ key blood biomarkers, and expert clinicians trained in genetics-informed preventive care and health action p

    $ME
    Biotechnology: Pharmaceutical Preparations
    Health Care

  • CORRECTION - 23andMe to Report Q2 FY2025 Financial Results

    SUNNYVALE, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- An earlier release under the same headline should have noted 23andMe Holding Co. (NASDAQ:ME) (23andMe) will report financial results for the second quarter of fiscal year 2025 (FY2025) prior to the market opening on Tuesday, November 12, 2024 (the prior release incorrectly stated the results would be reported after the market closes). The Company will webcast a conference call at 8:00 a.m. Eastern Time on that date to discuss the quarter's results and report on business progress. The webcast can be accessed on the day of the event at this link. A webcast replay will be available at the same address following the event. In addition, 23

    $ME
    Biotechnology: Pharmaceutical Preparations
    Health Care

  • 23andMe to Report Q2 FY2025 Financial Results

    SUNNYVALE, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (NASDAQ:ME) (23andMe), a leading human genetics and biopharmaceutical company, announced today that it will report financial results for the second quarter of fiscal year 2025 (FY2025) after the market closes on Tuesday, November 12, 2024. The Company will webcast a conference call at 4:30 p.m. Eastern Time on that date to discuss the quarter's results and report on business progress. The webcast can be accessed on the day of the event at this link. A webcast replay will be available at the same address following the event. In addition, 23andMe will use the Say Technologies platform to allow retail and institutional

    $ME
    Biotechnology: Pharmaceutical Preparations
    Health Care

$ME
 Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more